Battelle and subcontractor CMC Pharmaceuticals were selected by the U.S. Department of Defense (DOD) to develop an enhanced nerve agent countermeasure. This initiative aims to improve the current standard of care for warfighters and boost survival rates.
The program's goal is to create the Reactivating Nerve Agent Treatment System (RNATS), an improved reactivator in vial form designed for use by the U.S. military and its allies to defend against chemical threats—particularly nerve agents. These reactivator compounds work by restoring the function of the acetylcholinesterase (AChE) enzyme, which nerve agents disrupt.
